Attovia Therapeutics, Inc.
ATTO
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.1B
$25.55
▲ +5.58%
P/E
-19.21
Mkt Cap
$1.1B
52-Wk Range
$16.15–$27.66
52-Week Range
$16.15 - $27.66
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 16.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.0).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+16.7% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ATTO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
SEP 2, 2026
Reported EPS of -$4.88 vs -$0.65 consensus (-655.5% surprise). Revenue of $450.0K vs $316.7K expected (+42.1%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-655.5%
Revenue trend · last 3Q
—
—
—
Q1 25
Q1 26
Q2 26
$0
$0
$450.0K
Margins · last 3Q
Gross
45.3%
Profit
-4597.1%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 31, 2026
vs Industry
How ATTO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.